The C11orf68 Knockout HeLa Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical carcinoma line. This polyclonal population features targeted disruption of the C11orf68 gene via CRISPR/Cas9-mediated gene editing, yielding a heterogeneous pool of edited cells. The polyclonal knockout format enables efficient loss-of-function screening and pathway analysis without the selection bias inherent to clonal isolation, providing a flexible model for initial functional studies.
HeLa cells are an immortalized epithelial cell line originally isolated from an HPV-positive cervical adenocarcinoma. They are among the most extensively characterized cancer models, exhibiting robust proliferation and well-mapped oncogenic signaling pathways, including active PI3K-AKT and MAPK cascades. The line??s HPV E6 and E7 oncoproteins inactivate the tumor suppressors TP53 and RB, respectively, creating a cellular environment permissive for studying additional genetic perturbations in proliferation and apoptosis control.
C11orf68 is a gene of unknown function with a putative role in promoting cell proliferation and survival in cancers. Preliminary evidence positions C11orf68 downstream of key oncogenic regulators such as MYC and EGFR, and implicates it in modulating the PI3K-AKT signaling axis, likely via transcriptional regulation of cell cycle and apoptosis genes. Specifically, C11orf68 may influence the expression of CCND1 (cyclin D1), CDKN1A (p21), BCL2, and BAX, thereby controlling G1/S transition and mitochondrial apoptosis. Its knockout is anticipated to attenuate PI3K-AKT and MAPK signaling, leading to reduced proliferation, cell cycle arrest, and enhanced apoptotic susceptibility.
In the HeLa cervical carcinoma model, disruption of C11orf68 provides a valuable tool to dissect its contribution to HPV-driven oncogenesis. The host cell??s inactivation of TP53 and RB removes critical checkpoints, potentially heightening dependence on ancillary proliferative and anti-apoptotic pathways such as those involving C11orf68. Investigating C11orf68 loss in this background can uncover synthetic lethal interactions or compensatory mechanisms, and may clarify how C11orf68 intersects with PI3K-AKT and MAPK pathways to sustain tumor cell growth.
The C11orf68 Knockout HeLa Polyclonal Cells are suited for a wide array of functional genomics applications, including cancer cell line engineering, drug target identification, and mechanistic studies of proliferation and apoptosis. Researchers can employ western blotting and RT-qPCR to validate target disruption and downstream effector changes, MTT and colony formation assays to assess viability and clonogenicity, flow cytometry for cell cycle and apoptosis profiling, and wound healing assays to evaluate migration. These cells also serve as an ideal negative control for C11orf68 overexpression experiments or as a platform for screening small-molecule inhibitors that modulate the pathway. For technical inquiries or additional product information, please contact Ascent Research.
